-
EP3810647
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3810647
| EP3810647 - METHODS AND COMPOSITIONS FOR TREATMENT OF HEMOPHILIA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 26.03.2021 Database last updated on 15.06.2024 | |
| Former | The international publication has been made Status updated on 02.11.2019 | Most recent event Tooltip | 13.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The University of North Carolina at Chapel Hill 109 Church Street Chapel Hill, North Carolina 27516 / US | [2021/17] | Inventor(s) | 01 /
LI, Chengwen 210 Beringer Place Chapel Hill, North Carolina 27516 / US | 02 /
SUN, Junjiang 117 Vintage Drive Chapel Hill, North Carolina 27516 / US | [2021/17] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
| Former [2021/17] | HGF 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 19791892.3 | 26.04.2019 | [2021/17] | WO2019US29374 | Priority number, date | US201862663061P | 26.04.2018 Original published format: US 201862663061 P | [2021/17] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019210187 | Date: | 31.10.2019 | Language: | EN | [2019/44] | Type: | A1 Application with search report | No.: | EP3810647 | Date: | 28.04.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.10.2019 takes the place of the publication of the European patent application. | [2021/17] | Search report(s) | International search report - published on: | KR | 31.10.2019 | (Supplementary) European search report - dispatched on: | EP | 19.07.2022 | Classification | IPC: | C07K14/745, C12N15/62, C12N15/65, C12N15/86, A61K38/36, A61K48/00 | [2021/17] | CPC: |
C07K14/745 (EP,US);
A61K48/0058 (EP,US);
A61K48/005 (EP);
A61K48/0083 (US);
A61P7/04 (US);
C12N15/86 (EP,US);
A61K38/00 (EP);
C07K2319/02 (EP,US);
C12N2740/15023 (US);
C12N2740/15043 (US);
C12N2750/00042 (US);
C12N2750/14122 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/17] | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE | [2021/17] | English: | METHODS AND COMPOSITIONS FOR TREATMENT OF HEMOPHILIA | [2021/17] | French: | MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE L'HÉMOPHILIE | [2021/17] | Entry into regional phase | 23.02.2021 | National basic fee paid | 23.02.2021 | Search fee paid | 23.02.2021 | Designation fee(s) paid | 23.02.2021 | Examination fee paid | Examination procedure | deleted | Deletion: Application deemed to be withdrawn, date of legal effect [2021/17] | 17.12.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time [2021/17] | 23.02.2021 | Examination requested [2021/17] | 02.02.2023 | Amendment by applicant (claims and/or description) | Request for further processing for: | The application is deemed to be withdrawn due to non-payment of the search fee | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of the filing fee | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of the examination fee | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of designation fees TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL | 23.02.2021 | Request for further processing filed | 23.02.2021 | Full payment received (date of receipt of payment) Request granted | 05.03.2021 | Decision despatched | Fees paid | Renewal fee | 23.02.2021 | Renewal fee patent year 03 | 16.03.2022 | Renewal fee patent year 04 | 14.03.2023 | Renewal fee patent year 05 | 13.03.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]US7928199 (GRIFFIN JOHN H [US], et al) [X] 1-4 * see the whole document and in particular Fig.1, columns 7, 8 and Example 1. * [I] 5-14; | [Y]WO2016168728 (UNIV EMORY [US], et al) [Y] 15 * the whole document and in particuler SEQ ID NO:128.;; example 2 *; | [Y]WO2016181122 (UCL BUSINESS PLC [GB]) [Y] 15 * the whole document and in particuler SEQ ID NO:2. *; | [Y]WO2017021359 (MYODOPA LTD [GB]) [Y] 15 * the whole document and in particuler SEQ ID NO:39. *; | [XI] - RAFFAELLA TOSO AND RODNEY M CAMIRE, "Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20040501), vol. 279, no. 20, doi:10.1074/JBC.M402107200, ISSN 0021-9258, pages 21643 - 21650, XP008130633 [X] 1-4 * see the whole document and in particular the abstract; page 21644 right hand column third paragraph; paragraph bridging left and right column of page 21644; page 21643, four last lines. * [I] 5-14 DOI: http://dx.doi.org/10.1074/jbc.M402107200 | [XI] - VAN DER NEUT KOLFSCHOTEN MARIJN ET AL, "The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181.", THROMBOSIS AND HAEMOSTASIS, (200303), vol. 89, no. 3, ISSN 0340-6245, pages 429 - 437, XP002806089 [X] 1-4 * see the whole document and in particular "Results" and Fig.1. * [I] 5-14 DOI: http://dx.doi.org/10.1021/cm011734t | [XI] - NEUT KOLFSCHOTEN VAN DER MARIJN ET AL, "Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 8, doi:10.1074/JBC.M308574200, ISSN 0021-9258, (20040220), pages 6567 - 6575, (20031202), XP002587982 [X] 1-4 * see the whole document and in particular "Results" and Fig.1. * [I] 5-14 DOI: http://dx.doi.org/10.1074/JBC.M308574200 | [XI] - GALE A J ET AL, "Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C", PROTEIN SCIENCE, WILEY, US, (20020901), vol. 11, no. 9, doi:10.1110/PS.0210002, ISSN 0961-8368, pages 2091 - 2101, XP002324437 [X] 1-4 * see the whole document and in particular Fig.2A. * [I] 5-14 DOI: http://dx.doi.org/10.1110/ps.0210002 | [Y] - MCINTOSH JENNY ET AL, "Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 121, no. 17, doi:10.1182/BLOOD-2012-10-462200, ISSN 0006-4971, (20130425), pages 3335 - 3344, (20201119), XP086510295 [Y] 15 * Introduction * * abstract * DOI: http://dx.doi.org/10.1182/blood-2012-10-462200 | [Y] - Dutheil, Nathalie; Henckaerts, Els; Kohlbrenner, Erik; Linden, R. Michael, "DNA (human gene MBS85 promoter region-containing fragment)", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20100217), Database accession no. 2009:1488686-1206742-27-9, XP002807025 [Y] 15 * the whole document * | International search | [Y]US2002182670 (LOLLAR JOHN S [US]) [Y] 20 * See paragraph [0071]. *; | [A]US7306913 (DEVLIN JAMES J [US], et al) [A] 1-5, 17-24, 36, 37* See the whole document. *; | [Y]US8236764 (CAMIRE RODNEY M [US], et al) [Y] 1-5, 17-23 * See claim 1; columns 3-4; figure 5. *; | [YA]US2015353911 (SALAS JOE [US], et al) [Y] 1-5, 17-23 * See claims 1, 4, 80 and 82; paragraphs [0048], [0077], [0078], [0175]-[0177], [0199] and [0322]; SEQ ID NO: 17. * [A] 24, 36, 37; | [Y]WO2017053677 (BIOMARIN PHARM INC [US]) [Y] 23 * See paragraph [0105]; figure 1. *; | [Y] - SUN, J. et al., "Gene delivery of activated Factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies", Human Gene Therapy, (20170000), vol. 28, no. 8, pages 654 - 666, XP055646398 [Y] 23 * See abstract; figure 2. * DOI: http://dx.doi.org/10.1089/hum.2017.016 |